Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)

Clinical trial NCT03510871 · COMPLETED

Trial details

NCT number: NCT03510871
Sponsor: National Health Research Institutes, Taiwan
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Hepatocellular Carcinoma (HCC)

Start date: 2019-02-12
Primary completion: 2024-05-31
Enrollment: 43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.